Cargando…

Improvement in symptom-related disruptions is associated with fewer days of short-acting beta-agonist use in asthma

Significant indirect healthcare costs are related to uncontrolled asthma, including productivity loss. Days with short-acting beta-agonist (SABA) use is associated with symptom-related disruptions at work, home, and school. Digital self-management platforms may support fewer days with SABA medicatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaye, Leanne, Vuong, Vy, Barrett, Meredith A., Boers, Elroy, Guilbert, Theresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438376/ https://www.ncbi.nlm.nih.gov/pubmed/36056022 http://dx.doi.org/10.1038/s41533-022-00299-3

Ejemplares similares

Retrospective assessment of a collaborative digital asthma program for Medicaid-enrolled children in southwest Detroit: reductions in short-acting beta-agonist (SABA) medication use
por: Barrett, Meredith, et al.
Publicado: (2023)

Prediction of short-acting beta-agonist usage in patients with asthma using temporal-convolutional neural networks
por: Hirons, Nicholas, et al.
Publicado: (2023)

Changes in remote care adoption for asthma during the COVID-19 pandemic
por: Kaye, Leanne, et al.
Publicado: (2022)

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany
por: Woehrle, Holger, et al.
Publicado: (2023)

Passive Monitoring of Short-Acting Beta-Agonist Use via Digital Platform in Patients With Chronic Obstructive Pulmonary Disease: Quality Improvement Retrospective Analysis
por: Chen, Jessica, et al.
Publicado: (2019)

Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
por: Magee, Jared S., et al.
Publicado: (2018)

Factors Associated with Failure of Intermittent Nebulization with Short-Acting Beta-Agonists in Children with Severe Asthma Exacerbation
por: Kulalert, Prapasri, et al.
Publicado: (2020)

Loss of Asthma Control in Pediatric Patients after Discontinuation of Long-Acting Beta-Agonists
por: R. O'Hagan, Adrian, et al.
Publicado: (2012)

Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid
por: Dreher, Michael, et al.
Publicado: (2018)

Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany
por: Worth, Heinrich, et al.
Publicado: (2021)

Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study
por: Lee, Hyun, et al.
Publicado: (2021)

Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: A national study in Malaysia
por: Chin, May Chien, et al.
Publicado: (2017)

Reducing short-acting beta-agonist overprescribing in asthma: lessons from a quality-improvement prescribing project in East London
por: De Simoni, Anna, et al.
Publicado: (2022)

Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome
por: Lee, Suh-Young, et al.
Publicado: (2016)

“Tossing a coin:” defining the excessive use of short-acting beta(2)-agonists in asthma—the views of general practitioners and asthma experts in primary and secondary care
por: McKibben, Shauna, et al.
Publicado: (2018)

Developing a Smartphone Application That Promotes Responsible Short-Acting Beta2-Agonist Use in People with Asthma: A Participatory Design
por: van den Berg, Liselot N., et al.
Publicado: (2022)

RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2008)

Retraction Note to: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all?
por: Postma, Dirkje S., et al.
Publicado: (2009)

The relationship between objective app engagement and medication adherence in asthma and COPD: a retrospective analysis
por: Kaye, Leanne, et al.
Publicado: (2021)

Short-acting beta-2 agonist prescription patterns and clinical outcomes in Chinese patients with asthma: an observational study in mainland China for the SABINA programme
por: Bao, Wuping, et al.
Publicado: (2022)

Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia
por: Wang, Hao-Chien, et al.
Publicado: (2023)

Global Initiative for Asthma 2021: Asthma in Preschool Children and Short-Acting β(2)-Agonist–Only Treatment
por: Baraldi, Eugenio, et al.
Publicado: (2022)

Author Correction: “Tossing a coin:” defining the excessive use of short-acting beta2-agonists in asthma—the views of general practitioners and asthma experts in primary and secondary care
por: McKibben, Shauna, et al.
Publicado: (2019)

SABINA: An Overview of Short-Acting β(2)-Agonist Use in Asthma in European Countries
por: Janson, Christer, et al.
Publicado: (2020)

The prevalence and outcome of short-acting β2-agonists overuse in asthma patients in Taiwan
por: Wang, Cheng-Yi, et al.
Publicado: (2021)

It is time to end our love affair with short-acting β(2)-agonists in asthma
por: Crooks, Michael G., et al.
Publicado: (2022)

Short-acting β(2)-agonists and exacerbations in children with asthma in England: SABINA Junior
por: Morgan, Ann, et al.
Publicado: (2023)

Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
por: Vertadier, Nicolas, et al.
Publicado: (2022)

Over-the-counter use of short-acting beta-2 agonists: a systematic review
por: Loh, Zhe Chi, et al.
Publicado: (2023)

Real-Life Patterns of Exacerbations While on Inhaled Corticosteroids and Long-Acting Beta Agonists for Asthma over 15 Years
por: McGeachie, Michael J., et al.
Publicado: (2020)

Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic
por: Kaye, Leanne, et al.
Publicado: (2020)

Perceptions of Environmental Influence and Environmental Information-Seeking Behavior Among People With Asthma and COPD
por: Parikh, Shivani, et al.
Publicado: (2022)

The benefits of combined treatment with corticosteroids and long-acting beta agonists
por: Singh, Dave
Publicado: (2006)

Long-Acting Beta Agonists Enhance Allergic Airway Disease
por: Knight, John M., et al.
Publicado: (2015)

Applying the Risk of Bias Tool in a Systematic Review of Combination Long-Acting Beta-Agonists and Inhaled Corticosteroids for Persistent Asthma
por: Hartling, Lisa, et al.
Publicado: (2011)

Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD
por: Scichilone, Nicola, et al.
Publicado: (2014)

Infections and Asthma
por: Guilbert, Theresa W., et al.
Publicado: (2010)

Is overreliance on short-acting β(2)-agonists associated with health risks in the older asthma population?
por: To, Teresa, et al.
Publicado: (2022)

It is time to end our love affair with short-acting β(2)-agonists in asthma? Yes
por: Nannini, Luis J.
Publicado: (2023)

The use of electronic alerts in primary care computer systems to identify the excessive prescription of short-acting beta(2)-agonists for people with asthma: a systematic review
por: McKibben, Shauna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n09e74sbn5j03hvfgtdailrqfl